• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Lorcaserin does not increase rate of cardiovascular events in overweight or obese patients

byDayton McMillan
September 25, 2018
in Cardiology, Chronic Disease, Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. At a median follow-up of 3.3 years, rates of composite cardiovascular events in at-risk overweight or obese patients treated with lorcaserin were not significantly worse than for placebo treated patients.

2. Lorcaserin treated patients had significantly greater weight loss at 1 year compared to placebo treated patients.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Rates of obesity have drastically increased around the world in recent decades. Associated conditions which cause significant morbidity and mortality such as diabetes and stroke have risen alongside obesity. In addition to dietary and activity lifestyle modifications, pharmaceutical treatments could serve as an important treatment for overweight and obese patients. The 5-hydroxy-tryptamine 2C serotonin receptor agonist lorcaserin alters appetite and is of interest for treatment of overweight and obese patients. The CAMELLIA–TIMI 61 (Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61) trial investigated long-term cardiovascular and metabolic safety of lorcaserin in overweight patients with cardiovascular disease. The primary outcome of major cardiovascular events at a median follow-up of 3.3 years showed patients randomized to lorcaserin had similar outcomes as placebo treated patients. Weight loss of greater than 5% occurred in significantly more lorcaserin patients at 1 year.

Strengths of this study include its randomized design, detailed adverse event reporting, and inclusion of patients with multiple cardiac risk factors. Limitations include access to diet and exercise support during the study which is not generalizable to most patients, absent description of proportion of muscular or fat changes during weight loss, and absent reporting of weight loss comparisons at 3.3 years of follow-up. Overall, this study provides strong support to the cardiovascular safety of an important adjuvant therapy for weight loss in overweight or obese patients.

Click to read the study in NEJM

Relevant Reading: Multicenter, placebo-controlled trial of lorcaserin for weight management

RELATED REPORTS

Time restricted eating not more beneficial than daily calorie restriction

Weight loss and lifestyle changes may improve symptoms of obstructive sleep apnea in overweight men

Obesity may be associated with better response to immune checkpoint blockade therapy

In-Depth [randomized controlled trial]: Patients were recruited and randomized to study groups from 2014 to 2015. Eligible patients had a body mass index (BMI) of at least 27 and had one or more cardiovascular risk factors. Patients were treated with lorcaserin (n=6000) or placebo (n=6000) and followed for a median of 3.3 years. Over half of all patients studied had diabetes, hypertension, hyperlipidemia, or atherosclerotic cardiovascular disease. Discontinuation of patients in the study occurred at approximately 12% per year in both study groups. At 1 year, the mean change in weight from baseline was -4.2kg in the lorcaserin group and -1.4kg in the placebo group (P<0.001). Weight loss of at least 5% or 10% at 1 year occurred in a greater proportion of treated patients compared to placebo patients (P<0.001 for both comparisons). The primary outcome of major cardiovascular events occurred in 2.0% of patients per year in the treatment group and 2.1% of patients per year in the placebo group (hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.85 to 1.14; P<0.001 for noninferiority). Incidence of serious adverse events was similar between both groups. Of patients who had both baseline and 1-year cardiac echocardiograms performed, worsening valvulopathy occurred in 1.8% and 1.3% of treated and placebo patients, respectively (P=0.24).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Lorcaserinobesity
Previous Post

2 Minute Medicine Rewind September 24, 2018

Next Post

Current guidelines may not provide adequate instruction for prescribing anticoagulation in patients with atrial fibrillation

RelatedReports

Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Time restricted eating not more beneficial than daily calorie restriction

May 13, 2022
Admission may not be needed following sleep apnea surgery
Chronic Disease

Weight loss and lifestyle changes may improve symptoms of obstructive sleep apnea in overweight men

April 28, 2022
Many new pediatric asthma cases attributable to obesity
Chronic Disease

Obesity may be associated with better response to immune checkpoint blockade therapy

April 1, 2022
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Wellness Check: Nutrition

March 31, 2022
Next Post
Bystander and first-responder initiated CPR associated with improved outcomes

Current guidelines may not provide adequate instruction for prescribing anticoagulation in patients with atrial fibrillation

Estimated costs of clinical trials for FDA approval of novel therapeutics

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

Atorvastatin loading before percutaneous coronary intervention improves outcomes in patients with acute coronary syndrome

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
  • #VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.